Results 111 to 120 of about 4,378 (171)

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. [PDF]

open access: yesEur J Nucl Med Mol Imaging
Wenzel M   +11 more
europepmc   +1 more source

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer. [PDF]

open access: yesMed Int (Lond), 2023
Makita K   +8 more
europepmc   +1 more source

Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study. [PDF]

open access: yesEJNMMI Rep
Souza S   +27 more
europepmc   +1 more source

Exhalation of Rn-219 by patients treated with Radium-223. [PDF]

open access: yesEJNMMI Phys
Wanke C   +3 more
europepmc   +1 more source

Outcomes and Factors Associated with Completion of Radium-223 Therapy. [PDF]

open access: yesNucl Med Mol Imaging, 2022
Liu RF, Juwara L, Ferrario C, Probst SM.
europepmc   +1 more source

Prostate cancer – Therapy with radium-223 [PDF]

open access: yesRevista da Associação Médica Brasileira, 2017
Ana Emília, Brito   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy